More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 2

Co-Diagnostics completed clinical and analytical studies for its PCR Flu A/B & RSV test and plan

Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in hono

Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnosti

Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro® and expanding menu

Longstanding distribution partner to support future deployment of Co-Dx™ PCR Pro ® and expanding men

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regio

Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regio

A structural shift is underway in the biodefense landscape. The declaration of a Public Health Emerg

 Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnost

Joint development strategy has been developed to address international deployment requirements if cu

Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD

Co-Diagnostics shares jump 28% following a $3.0M private placement and key progress on its Bundibugy

SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx", or the "C

Recent pathogens illustrate need for improved situational awareness capabilities, such as those prov

https://www.cdc.gov/ebola/situation-summary/index.html

Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript

Advancing Global Commercialization Through CoSara Regulatory Progress and Regional Expansion Executi

he lease execution represents a key milestone as CoMira advances domestic manufacturing capabilities

Lease execution highlights transition from approval to development and advances localized manufactur

SALT LAKE CITY, April 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the

MTB test on Co-Dx PCR platform* to be presented at roundtable with Stop TB Partnership, U.S. Departm

Company to engage with global customers and distributors while expanding international commercial re

Trade mission itinerary of business, government, and industry briefings across Switzerland and Germa

Facility in Sudair Industrial City is expected to position CoMira among the early domestic manufactu

Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript

Co-Diagnostics (OTC:CODX) reported quarterly losses of $(16.65) per share. This is a 53.88 percent d

Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures Progressing Cli

The near-term commencement of clinical studies is expected to align with recent WHO tuberculosis rec

These materials are necessary to begin clinical performance studies of the TB test on the PCR platfo

Co-Diagnostics ships PCR Pro and TB test kits to India, advancing clinical studies as the WHO backs